Using a validated tetracycline (tet)-regulated MCF7-founder (MCF7F) expression system to modulate expression of CD44 standard form (CD44s), we report the functional importance of CD44s and that of a novel transcriptional target of hyaluronan (HA)/CD44s signaling, EMS1/cortactin, in underpinning breast cancer metastasis. In functional experiments, tet-regulated induction of CD44s potentiated the migration and invasion of MCF7F cells through HA-supplemented Matrigel. EMS1/cortactin was identified by expression profiling as a novel transcriptional target of HA/CD44 signaling, an association validated by quantitative PCR and immunoblotting experiments in a range of breast cancer cell lines. The mechanistic basis underpinning CD44-promoted transcription of EMS1/cortactin was shown to be dependent upon a NFjB mechanism, since pharmacological inhibition of IjKinase-2 or suppression of p65 Rel A expression attenuated CD44-induced increases in cortactin mRNA transcript levels. Overexpression of a c-myc tagged murine cortactin construct in the weakly invasive, CD44-deficient MCF7F and T47D cells potentiated their invasion. Furthermore, the functional importance of cortactin to CD44s-promoted metastasis was demonstrated by selective suppression of cortactin in CD44-expressing MCF7F-B5 and MDA-MB-231 breast cancer cells using RNAi, which was shown to result in attenuated CD44-promoted invasion and CD44-promoted adhesion to bone marrow endothelial cells (BMECs).
Introduction
Breast cancer is frequently associated with the overexpression of EMS1 (Schuuring et al., 1992; Rodrigo et al., 2000) , the gene that encodes cortactin. Clinical studies have demonstrated that elevated cortactin levels correlate with poor prognosis or relapse in patients (Hui et al., 1997; Rodrigo et al., 2000) . Cortactin interacts with F-actin, promoting the activation of the Arp2/3 complex to facilitate branching of actively polymerizing actin bundles and the generation of stress fibers (Mullins, 2000; Urono et al., 2001; Weaver et al., 2001) . Recently, cortactin has been shown to enhance lamellipodial persistence and the rate of adhesion formation in lamellipodia, consistent with an important function in regulating directed cell motility (Bryce et al., 2005) . In addition, cortactin promotes communication between the cell and its extracellular environment by modulating the clustering of ICAM-1 and selectin receptors on endothelial cells in order to promote adherence of leukocytes at sites of inflammation (Tilghman and Hoover, 2002) and platelet arrest on collagen under flow conditions (Arderiu et al., 2002) . Furthermore, cortactin plays an important role in regulating Ncadherin-mediated intercellular adhesion strength (Sayegh et al., 2005) . Similarly, in breast cancer cells the overexpression of cortactin regulates cell motility and adhesion; for example, cortactin was shown to complex with paxillin and PKCm within invadipodia of actively invading breast cancer cells (Bowden et al., 1999) while overexpression of cortactin in metastatic breast cancer cells was shown to increase cell invasion and their ability to adhere to bone marrow endothelial cells . Of considerable therapeutic relevance to the treatment of breast cancer, recent findings have shown that cortactin overexpression inhibits the ubiquitination-mediated degradation of the epidermal growth factor receptor following its internalization, resulting in a sustained ligand-induced epidermal growth factor receptor activity (Timpson et al., 2005; van Rossum et al., 2005) . Consequently, cortactin overexpression may potentiate both the mitogenic and motogenic function of EGF-signaling in breast cancer cells.
Stromal hyaluronan (HA) levels are a strong, independent, negative predictor for patient survival in breast cancer (Auvinen et al., 2000; Toole, 2000) . Hyaluronan (HA) mediates communication between a cancer cell and its environment via interactions with cell surface receptors of the hyaladherin family, the best known of which is CD44 (Lee and Spicer, 2000; Isacke and Yarwood, 2002) . CD44 expression in breast cancer has been correlated with nodal metastasis and disease progression (Kinoshita et al., 2000; Berner and Nesland, 2001 ). Animal models of breast cancer tumorigenicity have identified CD44 expression as one of two cell surface markers that differentiates tumorigenic (tumor initiating) from non-tumorigenic breast cancer cells in immuno-compromised mice (AlHajj et al., 2003) . In addition, animal models have provided compelling evidence establishing the role of CD44 in cancer metastasis. In these studies, mice carrying the min mutation of the APC gene or the tm1 mutation of the p53 gene were crossed with CD44 knockout mice. Although mice lacking CD44 developed a similar incidence of primary tumors in response to the APC or p53 gene mutations as the CD44 expressing mice, knocking out CD44 resulted in a complete inability of these mice to develop metastatic lesions (Weber et al., 2002) . In vitro studies have also demonstrated that HA promotes the invasion of breast cancer cells through experimental extracellular matrices as a consequence of activating CD44 (Herrera-Gayol and Jothy, 2001) . Our laboratory has also recently established a role for CD44 expression in breast and prostate cancer cells in promoting their preferential adhesion to bone marrow endothelial cells (Draffin et al., 2004) . This observation suggests that HA/CD44 function and signaling may underpin the high incidence of bone metastasis observed in patients with relapsed or progressive breast or prostate cancer (Kozlow and Guise, 2005) .
Modulation of cell motility and cell adhesion is essential for metastasis and arises as a result of changes in the cytoskeletal architecture (Lester and McCarthy, 1992; Yamaguchi et al., 2005) . CD44 integrates with the cell cytoskeleton through its capacity to complex with members of the ezrin-radixin-moeisin family (Tsukita et al., 1994; Hirao et al., 1996) and reported complex formation with ankyrin Bourguignon et al., 1999) . Several studies have demonstrated that CD44 may modulate the dynamics of the cytoskeleton through its ability to activate a number of small GTPases including Rac1 and RhoA that promote cytoskeleton associated membrane ruffling at the leading edge of the cell (Tsukita et al., 1994; Bourguignon et al., 1998 Bourguignon et al., , 2000 Bourguignon et al., , 2004 Oliferenko et al., 2000) . In addition, CD44 has been reported to promote Src-kinase activation, a downstream effector of which is the SH2-domain of cortactin (Bourguignon et al., 2001) .
The objective of this study was to establish a CD44-inducible expression system to identify and validate the largely unknown transcriptional targets of HA/ CD44 signaling in breast cancer cells. Here we demonstrate the novel relationship between HA/CD44 signaling and the transcription of cortactin in breast cancer cells and validate cortactin as an important intermediate effector in modulating the CD44-promoted invasion and adhesion of breast cancer cells to bone marrow endothelium.
Results
Characterization of the inducible CD44s-expression system CD44 expression and distribution on the MCF7 TetOfft breast adenocarcinoma founder cell line (MCF7F) was analyzed by northern blotting, RT-PCR, immunoblotting and indirect immuno-fluorescence (data not shown). Minimal CD44 expression was detected in the MCF7F cell line using either of these techniques indicating that this founder cell line was appropriate to use to generate an inducible CD44 expression system.
A tetracycline-regulated, inducible CD44 expression system was generated by transfection of the MCF7F cell line with a pUHD 10-3 tetracycline inducible vector incorporating the full-length coding sequence of CD44s. Transfected clones were amplified under selection with Geneticin s (G418) and analyzed for CD44 expression by northern blotting, western blotting and immunocytochemistry. Tetracycline-regulated control of CD44s expression in the MCF7F cell line by altering the presence of tetracycline (tet) in the culture media is shown for clone B5. Using northern blotting, the presence of CD44 mRNA was demonstrated by the detection of three transcripts that arise as a result of differential transcription of the 3 0 untranslated region of the CD44 gene, the lower band (1.0 kb) representing the coding sequence of the CD44 gene ( Figure 1a ). The presence of mRNA for CD44s in the MCF7F-B5 clone was investigated in a time-course study over a period of 48 h, conducted on cells cultured in the presence and absence of tet. An increased CD44 mRNA transcript level was detectable in the -tet cultured cells throughout the time course with increases detectable at all time points studied reaching a maximum level 48 h post-tet removal.
Similarly, the expression of CD44 protein in the MCF7F-B5 clone was studied over a 48 h time course in the presence and absence of tet. Protein was extracted at 6, 12, 24 and 48 h (Figure 1b) , resolved by SDS-PAGE and probed for CD44 expression using a mouse antihuman CD44 mAb. A single immunoreactive band was detected at a molecular mass equivalent to 85 kDa, consistent with the presence of CD44s. Increased CD44s expression was first detectable within 6 h with peak overexpression detectable at 48 h. Analysis over an extended time course confirmed that inducible CD44s expression was maintained out to 96 h in this system (data not shown). Immunocytochemistry was conducted on cultured MCF7F-B5 cells in which CD44 expression was induced (-tet) for 24 h before immunolabeling with a mouse anti-human CD44 mAb. Cell nuclei were counterstained with propidium iodide. A high level of CD44 expression with strong punctate cell surface distribution was evident in cells cultured in the absence of tet (Figure 1c , top right). In comparison, MCF7F-B5 cells cultured in tet showed weak CD44 expression ( Figure 1c, top left) . Furthermore, when MCF7F-B5 cells were labeled with FITC-conjugated HA, cells with tet-induced CD44 expression exhibited strong fluorescence associated with the cell surface ( Figure 1c , bottom right) consistent with the punctate cell surface distribution of CD44 previously demonstrated. In contrast, minimal fluorescence was associated with the MCF7F-B5 cells cultured in the presence of tet consistent with the negligible cell surface CD44 expression. Together these results confirm the establishment of an inducible CD44 expression system that promotes increased cell surface expression of a functionally active protein. All further experiments were conducted in the B5 clone (MCF7F-B5).
Induction of CD44 expression increases the invasive potential of MCF7F-B5 cells
The effect of induced CD44s expression (Figure 2a ) on the invasive potential of MCF7F-B5 cells was assessed using cell migration and cell invasion assays. The migratory phenotype resulting from elevated CD44 expression in MCF7F-B5 cells was demonstrated using an in vitro Boyden chamber assay conducted on a reconstituted HA matrix. Cells that traversed the HA matrix over the course of 16 h were stained with Hoechst reagent, counted under high magnification and the % migration calculated. MCF7F-B5 cells exhibited low basal migratory capacity (mean of 2.38870.7398% of total cell number, n ¼ 3). Induction of CD44s expression on MCF7F-B5 cells upon removal of tet increased their migration potential (mean of 11.6672.422% of total cell number, n ¼ 3, P ¼ 0.0215) (Figure 2b Analysis of the microarray data set predicted a 2.12-fold increase in EMS1/cortactin mRNA transcript levels in response to HA/CD44 signaling. Cortactin was chosen for further study on the basis that it is an oncogene frequently amplified in breast cancer (Rodrigo et al., 2000) , that it is associated with cytoskeletal remodeling (Mullins, 2000; Urono et al., 2001; Weaver et al., 2001) , that it has previously been identified as a post-translational target of CD44 signaling (Bourguignon et al., 2001) and has been associated with increased invasion and adhesion of breast cancer cells (Bowden et al., 1999; Li et al., 2001) . Quantitative PCR (qPCR) analysis was initially conducted on surplus mRNA stocks on which the microarray analysis was performed. In this analysis, CD44 mRNA levels were 18.81-fold and 24.32-fold higher in MCF7F-B5 cells following the removal of tet at 12 and 24 h post-HA stimulation, respectively ( Figure 3a To further validate the relationship between CD44 expression and the levels of cortactin expression in these breast cancer cells, we sought to demonstrate a loss of cortactin mRNA levels in MCF7F-B5 cells (-tet) following RNAi-mediated suppression of CD44 expression. Transfection of cells with a CD44 exon 3-targeted oligonucleotide reduced CD44 mRNA levels by 56.8% relative to scrambled oligonucleotide-transfected cells ( Figure 3c , left panel). This correlated with a 35.6% reduction in the levels of cortactin mRNA detected in CD44-depleted MCF7F-B5 cells relative to scrambled oligonucleotide treated cells ( Figure 3c , right panel).
The temporal relationship of HA-induced CD44 signaling to cortactin gene regulation was studied by analysis of cortactin mRNA levels in MCF7F-B5 cells following exposure to 100 mg/ml HA (MW 220 kDa). Experiments were conducted on cells cultured for 24 h in tet-free media to ensure induction of CD44 expression. Increased cortactin mRNA levels were detected as early as 1 h post HA stimulation reaching a peak fourfold induction 6 h after addition of exogenous HA to MCF7F-B5 cells (Figure 4a ). Furthermore, immunoblotting confirmed a time-dependent increase in cortactin expression in CD44-expressing MCF7F-B5 cells upon stimulation with 100 mg/ml HA, with increases detectable 3 h post-addition and maintained for periods out to 12 h post-HA stimulation ( Figure 4b ). We also observed the emergence of a higher molecular weight immunoreactive band in response to HA stimulation in these cells; however, the nature of this immunoreactive cortactin band remains to be established in further proteomic studies.
We also addressed the cell line specificity of the relationship between CD44 and the regulation of cortactin transcription/expression using the CD44-expressing MDA-MB-157 breast cancer cell line. As expected, qPCR analysis confirmed that stimulation of MDA-MB-157 cells with 100 mg/ml HA induced a timedependent increase in the cortactin mRNA transcript level. In these cells, HA-stimulation was shown to increase cortactin mRNA transcript levels with a peak induction 2.14-fold of that detected in unstimulated cells ( Figure 5a ). Again, suppression of CD44 expression using RNAi to 30% of control levels ( Figure 5b , left panel) correlated with a reduction of cortactin levels to 68.8% (n ¼ 3) of that detected in scrambled oligonucleotide-transfected MDA-MB-157 cells (Figure 5b , right panel). Similar results were observed using the CD44s-expressing prostate cancer cell line PC3 (Draffin et al., 2004) in which transfection with the CD44 exon 3-targeted oligonucleotide reduced cortactin mRNA levels to 75.875.7% of that detected in the scrambled oligonucleotide-transfected cell population (data not shown). Therefore, we have exploited several different strategies to demonstrate a 'gain' and 'loss' of cortactin expression following modulation of HA/ CD44 signaling in several cancer cell lines.
NFkB activation couples CD44 to transcription of cortactin in breast cancer cells To elucidate the signal transduction pathways coupling CD44 to the regulation of cortactin transcription, CD44 Cortactin underpins CD44-promoted metastasis A Hill et al expression was induced in MCF7F-B5 cells by removal of tet from the growth media, following which the cells were stimulated with 100 mg/ml HA for 6 h in either the absence or presence of well-characterized signal transduction inhibitors. In the absence of any signal transduction inhibitor, CD44 signaling increased cortactin mRNA transcript levels by a mean value of 1.81-fold (n ¼ 5). Similar HA/CD44-promoted increases in cortactin mRNA levels were determined in MCF7F-B5 cells treated with an inhibitor of either PI3K (LY294002; 10 mM), PKC (bisindolemaleimide; 10 nM), Src-kinase (PP2; 5 nM) or a 0.15% (v/v) DMSO vehicle control. However, treatment with the IkKinase-2 inhibitor, SC-514 (20 mM) or the MEK1 inhibitor, U0126 (10 mM) abrogated the CD44-promoted increase in cortactin mRNA transcript levels to the level detected in unstimulated cells (Figure 6a ). The pharmacological approach using the IkKinase-2 inhibitor was complimented by RNAi-mediated suppression of the p65 Rel A subunit of NFkB in the MCF7F-B5 (-tet) cells. Western blotting confirmed that Rel A expression was suppressed in CD44-expressing MCF7F-B5 cells using this oligonucleotide ( Figure 6b ). qPCR analysis confirmed that suppression of Rel A decreased the cortactin mRNA transcript levels to 68.9% of that detected in scrambledoligonucleotide transfected cells (Figure 6c ). To confirm that CD44 signaling promoted the activation of NFkB, MCF7F-B5 cells were transfected with a pLuc-NFkB reporter plasmid, then stimulated with 100 mg/ml HA over a 3-h period. We observed timedependent increases in NFkB-driven luciferase activity with the peak increase detected 2 h post-addition of exogenous HA (Figure 6d) . Furthermore, the HAstimulated NFkB activity was attenuated by pretreatment with the IkKinase-2 inhibitor, SC-514 (20 mM) and by administration of the MEK1 inhibitor, U0126 (10 mM) (Figure 6e ). However, no such effect was observed using the 0.15% (v/v) DMSO vehicle control. Collectively, our experiments indicate that activation of NFkB underpins the transcriptional regulation of cortactin in response to CD44 signaling. Further experiments will be required to confirm that MEK1 is involved in coupling CD44 to the elevation of NFkB activity. 
Cortactin underpins CD44-promoted metastasis
A Hill et al
Cortactin underpins CD44 function in breast cancer cells
We determined the effect of increasing cortactin expression upon the invasion of the MCF7F and T47D breast cancer cell lines, both of which exhibit negligible endogenous CD44 expression and are poorly invasive. Each cell line was transfected with an expression plasmid encoding a c-myc-tagged murine cortactin construct which as expected increased cortactin expression in these cells (Figure 7a, upper panel) . Blotting for c-myc also confirmed the increased expression of the murine cortactin protein in the transfected cells but not in mock-transfected or untransfected cells (Figure 7a , middle panel). Overexpression of murine cortactin in MCF7F cells potentiated the invasion of this cell line; relative to mock-transfected cells (mean of 2.3970.19% of total cell number, n ¼ 3), the cortactin-transfected MCF7F cells invasion was increased 1.7-fold (mean of 4.0770.28% of total cell number, n ¼ 3, P ¼ 0.0012) (Figure 8b) . Similarly, the basal invasion of T47D cells was increased from 1.7670.15 of total cell number (n ¼ 3) to 2.6870.23% of total cell number (n ¼ 3, P ¼ 0.015) following overexpression of murine cortactin ( Figure 7c ). When similar experiments were conducted in the invasive MDA-MB-231 breast cancer cell line which expresses CD44, overexpression of murine cortactin increased the invasion from 18.0470.7% of total cell number (n ¼ 3) to 27.5170.86% of total cell number (n ¼ 3, P ¼ 0.001) (Figure 7d ). Therefore, increasing cortactin expression potentiates the invasive potential of breast cancer cells, irrespective of their baseline invasive potential. The functional significance of cortactin expression to CD44-promoted cell motility and adhesion was further studied by determining the effect of suppressing cortactin expression in the MCF7F-B5 clone expressing CD44 (tet-free media) and the MDA-MB-231 cell line. Transfection of the cortactin siRNA oligonucleotide at a final concentration of 50 nM reduced endogenous cortactin expression in each cell line (Figure 8a ). In contrast, transfection with a scrambled oligonucleotide had only a minimal effect on cortactin expression in either cell line. The HA/CD44-promoted invasiveness of MCF7F-B5 cells (mean of 7.0670.68% of total cell number, n ¼ 3) (Figure 8b , left panel) was markedly attenuated following the RNAi-mediated depletion of cortactin expression in these cells (mean of 4.3370.54% of total cell number, n ¼ 3, P ¼ 0.034). Similarly, abrogation of cortactin expression in MDA-MB-231 cells attenuated the HA/CD44-promoted invasiveness of these cells, reducing the invasion of mock-transfected cells from a mean value of 19.8370.83% of total cell number (n ¼ 3) to a mean value of 12.8170.29% total cell number (P ¼ 0.0014, n ¼ 3) in cortactin siRNA oligonucleotide transfected cells (Figure 8b, right panel) . Treatment with the scrambled oligonucleotide at an equivalent final concentration had a minimal effect upon the invasion of the MCF7F-B5 cell line (data not significant), but did have a confounding, statistically significant effect on MDA-MB-231 cell function at this concentration (P ¼ 0.015). Comparison of the response observed with the cortactin-Si1 oligonucleotide to that of the scrambled oligonucleotide determined a statistically significant difference (P ¼ 0.0033), confirming that oligonucleotide effects specific to the depletion of cortactin in this cell line do correlate with a reduction in cell invasion.
The effect of suppressing cortactin expression upon CD44-promoted adhesion of breast cancer cells to bone marrow endothelium was also investigated. MCF7F-B5 cells expressing CD44 (tet-free media) adhered rapidly to BMECs reaching a maximal adhesion of 6.9170.73% (n ¼ 4) within 20 min. In comparison, suppression of cortactin expression impaired the rate of adhesion of MCF7F-B5 cells to BMECs (Figure 8c , Cortactin underpins CD44-promoted metastasis A Hill et al left panel) with statistically significant decreases observed at 2 min (P ¼ 0.006), 6 min (Po0.001), 10 min (P ¼ 0.0085) and 20 min (P ¼ 0.038). Similarly, abrogating cortactin expression also had statistically significant effects upon the rate of MDA-MB-231 cell adhesion to BMECs at the 6 min (Po0.0066) and 20 min (Po0.036) time points (Figure 8c , right panel). Treatment with the scrambled oligonucleotide at an equivalent concentration had no effect upon the adhesion of either the MCF7F-B5 or MDA-MB-231 cell lines to BMECs. Therefore, our observations suggest that cortactin plays an important role in the CD44-initiated adhesion of breast cancer cells to BMECs.
Discussion
Although several upstream signaling events have been characterized for HA/CD44 signaling (Tsukita et al., 1994; Hirao et al., 1996; McKee et al., 1996; Bourguignon et al., 1998 Bourguignon et al., , 1999 Bourguignon et al., , 2000 Bourguignon et al., , 2001 Zhu and Bourguignon, 1998; Oliferenko et al., 2000) , the impact of HA/CD44 signaling on the cellular transcriptome is poorly understood. The aim of this study was to identify novel transcriptional targets of HA/CD44 signaling in breast cancer cells that may underpin cellular phenotypes associated with CD44-promoted metastasis of breast cancer. Central to the conduct of the study, we All experiments using the MCF7F-B5 inducible cell line were conducted following a 24-h incubation in tet-free media in order to induce CD44 expression. Data points shown are the mean7s.e.m. of three independent experiments, each conducted in triplicate. Statistical analysis of data points was conducted using a two-tailed Student's t-test. *Po0.05; **Po0.01; ***Po0.001.
developed and characterized a cell-based model system enabling inducible CD44 expression in a weakly metastatic breast cancer cell line that exhibits low endogenous expression of CD44. Northern blotting, RT-PCR and immunoblotting all confirmed that the transcription and expression of CD44s was induced in MCF7F-B5 cells following the removal of tet from the growth media. In support of the clinical association of CD44 expression with nodal metastasis, the induction of CD44s expression on MCF7F-B5 cells increased their migration and invasion through an experimental matrix. Following functional validation of this tet-regulated CD44 expression system, RNA was extracted from HA-stimulated MCF7F-B5 cells in the absence and presence of CD44 expression and the transcriptional targets of HA/CD44 signaling determined by microarray analysis. Prior studies have indicated that the fragment size of HA impacts on the signaling competency of CD44 (McKee et al., 1996; Fitzgerald et al., 2000) . Accordingly, RNA samples were harvested from cells stimulated with HA of an approximate molecular weight of 220 kDa.
One of the transcriptional targets of HA/CD44 signaling predicted by microarray analysis was EMS1/ cortactin, a gene whose expression is amplified in approximately 15% of breast cancers and whose increased expression correlates with poor prognosis or relapse in patients (Rodrigo et al., 2000) . Several other lines of evidence supported our initial rationale for further study of cortactin as a component of CD44-induced breast cancer metastasis. First of all, cortactin is a protein that promotes the polymerization of the actin cytoskeleton and is implicit to the ability of cells to alter their adherence status or become motile (Mullins, 2000; Urono et al., 2001; Weaver et al., 2001) . Cortactin has also previously been identified as a signaling target of CD44-activated p60 Src kinase (Bourguignon et al., 2001) , while other studies have demonstrated the localization of cortactin to the invadipodia of invasive breast cancer cells (Bowden et al., 1999) . Finally, modulation of cortactin activity in breast cancer cells has been shown to correlate with enhanced cell invasion and the ability of breast cancer cells to adhere to bone marrow endothelium in vitro and potentiate metastasis to the bone in vivo .
The HA/CD44-promoted increase in cortactin mRNA levels in MCF7F-B5 cells detected by microarray analysis was confirmed by qPCR analysis conducted on the RNA samples sent for microarray analysis. An increase of almost threefold in the 12-h-HA-stimulated sample was offset by no detectable increase in the 24-h-HA-stimulated sample, corresponding favorably with the 2.12-fold increase in cortactin mRNA predicted by microarray analysis of a pooled mRNA sample of the above time points. Similarly, time-dependent increases in cortactin mRNA levels were also observed upon HA stimulation of MCF7F-B5 cells and the metastatic breast cancer cell line, MDA-MB-157. As a complementary approach, we also demonstrated that cortactin mRNA levels decreased in MCF7F-B5 cells, MDA-MB-157 cells and PC3 cells, the later a metastatic prostate cancer cell line, when CD44 expression was suppressed by a selective RNAi-strategy. Therefore, using CD44-inducible systems or CD44-repression strategies, we have demonstrated the correlation between CD44 expression and cortactin mRNA levels in these breast and prostate cancer cells. Time-dependent, CD44-promoted increases in cortactin protein were also demonstrated by immunoblotting analysis of protein extracted from HAstimulated MCF7F-B5 cells, reinforcing the importance of HA/CD44 signaling in regulating cortactin expression in these cells.
We have also elucidated the temporal and mechanistic basis underpinning CD44-promoted regulation of cortactin transcription. Cortactin mRNA levels were shown to increase within one hour of exogenous HA stimulation in each of the breast cancer cells examined, peaking at a maximal level between 3 and 6 h post-stimulation with HA. Immunoblotting experiments confirmed elevation of cortactin expression within 3 h of HA-stimulation, with expression remaining elevated for 12 h. Activation of the NFkB transcription factor was implicated in the regulation of cortactin; pharmacological inhibition of NFkB using the IkKinase-2 inhibitor SC514 or RNAi-mediated inhibition of p65 Rel A expression were each shown to attenuate CD44-promoted increases in cortactin mRNA transcript levels in MCF7F-B5 cells. Furthermore, inhibition of IkK-2 was shown to attenuate the HA/ CD44-induced NFkB luciferase activity in reporter assays conducted in these breast cancer cells. Consistent with the temporal aspect of cortactin regulation, increases in CD44-induced NFkB luciferase activity were detectable within 40 min of adding exogenous HA, reaching a maximal level of activity 2 h post-stimulation with HA. Analysis of the cortactin promoter sequence does confirm the presence of several NFkB consensus binding sites.
Over-expression of GFP-tagged murine cortactin in the MDA-MB-231 breast cancer cell line was previously shown to potentiate both cell migration and cell adhesion to BMECs . To demonstrate the functional importance of cortactin in promoting cellular responses to HA/CD44 stimulation, we developed an RNAi-strategy to deplete endogenous and CD44-induced cortactin expression in MCF7F-B5 cells (-tet) and MDA-MB-231 cells. Oligonucleotide-specific suppression of cortactin expression in these cells was confirmed by immunoblotting. In comparison to mockor scrambled-oligonucleotide-transfected cells, depletion of cortactin expression decreased CD44-promoted invasion of MCF7F-B5 (-tet) and MDA-MB-231 cells. In addition, abrogation of cortactin expression attenuated CD44-initiated adhesion of these breast cancer cell lines to BMECs. Therefore, these results are consistent with the well established role of cortactin in modulating and promoting cell motility and further validate the emerging significance of cortactin in underpinning cell-endothelial cell adhesion. Specifically, our data also demonstrates the importance of cortactin in underpinning HA/CD44-induced cell motility and HA/ CD44-promoted adhesion of breast cancer cells to bone marrow endothelium in vitro. Accordingly, the potential dual regulation of cortactin at the transcriptional level as described in this current study and at the post-translational level as defined by prior studies (Bourguignon et al., 2001 ) may contribute to the CD44-promoted increases in invasion and cell adhesion of breast cancer cells.
In summary, we have developed a tet-regulated CD44s expression system in a weakly invasive breast cancer cell line. The induction of CD44s correlated with and was functionally important in increasing the migratory and invasive capacity of these breast cancer cells. We have validated that the cytoskeletal protein cortactin is a downstream transcriptional target of HA/CD44 signaling and demonstrated that cortactin is functionally important in underpinning CD44-promoted cell motility and adhesion to endothelial cells. To date, the overexpression of cortactin in breast cancer cells is principally associated with gene amplification of chromosome 11q13 (Schuuring et al., 1992; Rodrigo et al., 2000) . However, this study demonstrates that HA/ CD44 signaling can increase cortactin expression in breast cancer cells, reporting for the first time that an extracellular stimuli may not only modulate the posttranslational activation of this cytoskeletal protein but may also influence the regulation of its expression at the transcriptional level. The downstream effector/s and mechanism by which cortactin ultimately modulates the motility and adhesion of breast cancer cells remains to be established. However, studies investigating the adhesion of leukocytes to endothelial cells have shown that cortactin can regulate the activity of E-selectin and ICAM-1 (Arderiu et al., 2002; Tilghman and Hoover, 2002) . Therefore, cortactin may play an important role in communicating cell motility and adhesion signals initiated by CD44 signaling in breast cancer cells to other cell surface receptors involved in regulating motility and adhesion.
Materials and methods

Cells
The MCF7 tet-Offt (MCF7F) breast adenocarcinoma founder cell line (Clontech) containing the tetracycline (tet)-controlled transactivator (tTA) under selection with Geneticins (G418) was maintained in DMEM supplemented with 10% fetal calf serum (FCS), 1 mg/ml tet and 100 mg/ml G418 (Roche Diagnostics Ltd. (GmBH), Lewes, UK). MDA-MB-231, MDA-MB-157, T47D and PC3 cell lines were purchased from American Type Culture Collection (ATCC) (Manassas, VA, USA). All cells were cultured in DMEM media containing 10% (v/v) FCS, 2 mM L-glutamine and 1 mM sodium pyruvate (Life Technologies, Paisley, UK) except PC3 cells which were cultured in RPMI supplemented with 10% (v/v) FCS and 4 mM L-glutamine. The transformed human bone marrow endothelial cell line (Tr-hBMEC) was maintained in DMEM supplemented with 5% (v/v) FCS, 10 mM HEPES and 3 mM L-glutamine. All cell lines were grown to 70 or 80% confluence before experimentation.
Chemicals and reagents
Chemicals were supplied by the Sigma Chemical Co. (St Louis, MO) unless otherwise stated. Hyaluronan of MW 220 kDa and medical grade purity was purchased from Lifecore Biomedical Inc. (Chaska, MN) .
Generation of a breast cancer cell line with inducible CD44 expression The CD44s coding region was PCR-amplified using primers introducing an EcoR1 restriction site and Kozak sequence at the 5 0 end and an Xba1 restriction site at the 3 0 end, then ligated into the pUHD10-3 response plasmid downstream from the tetracycline (tet)-responsive element and the minimal CMV promoter. The inducible CD44 construct (10 mg) and a plasmid expressing the puromycin resistance gene (puroBabe) (1 mg) were co-transfected into MCF7F cells using Superfect reagent according to manufacturer's instructions (Quiagen, Chatsworth, CA). Selection was carried out in medium containing 1 mg/ml puromycin and resistant clones isolated and expanded by culture in DMEM media containing 10% (v/v) FCS, 2.5 mg/ml tet, 100 mg/ml G418, and 1 mg/ml puromycin. To analyze CD44 induction, cells were washed twice with sterile PBS and cultured in tet-free media for 24 h before screening for CD44 induction by northern blotting. Clone B5 was selected for further investigation.
Northern blotting
CD44s transcript levels were detected using a previously published protocol (Monaghan et al., 2000) .
Immunocytochemistry
CD44 immunolabeling was conducted on live cells grown on coverslips (13 mm diameter) to 80% confluence. Cells were washed in PBS and incubated with a 1:1000 dilution of clone 2C5 mouse anti-human CD44 antibody (R&D Systems, Abingdon, UK) for 30 min at room temperature. Cells were fixed in ice cold acetone for 10 min, air-dried, re-hydrated in PBS for 5 min and incubated for 30 min in rabbit anti-mouse IgG FITC-conjugated antibody (DAKO, Denmark) diluted 1:40 with PBS. In some experiments, cells were incubated with FITC-conjugated HA for 60 min before fixation. For nuclear counterstaining, the coverslips were incubated in propidium iodide (1.3 mg/ml in PBS) for 10 s, washed in PBS, mounted in Citifluor and examined by fluorescence microscopy (Leica DMLB, Heerbrugg, Switzerland).
Preparation of RNA samples and microarray analysis RNA was harvested from MCF7F-B5 cells cultured in the presence (no CD44 expression) and absence (strong CD44 expression) of tet following stimulation with HA (MW 220 kDa, 100 mg/ml) for 12 and 24 h using the RNAStat60 procedure. Harvested RNA was assessed for quantity and purity, then aliquoted and stored at À801C. RNA samples harvested at 12 and 24 h were pooled in equimolar fashion and sent for microarray analysis on an Affymetrix U133A microarray platform. Biochemical and functional validation of differential tet-regulated CD44 expression on the MCF7F-B5 cells at the time of RNA sample extraction was confirmed in parallel immunoblotting experiments and invasion assays.
Quantitative PCR analysis (qPCR) cDNA was synthesised from 10 mg total RNA primed with random hexamers (Invitrogent Life Technologies, Paisley, Scotland) and reverse transcribed with MMLV reverse transcriptase (Invitrogent Life Technologies, Paisley, Scotland) as per manufacturer's instructions. qPCR analysis was performed using the Opticon s 2 Continuous Fluorescence Detector (MJ Research). Product amplification was determined by SYBR Green 1 fluorescence detection. Primers used are as shown: CD44 Forward TTTGCATTGCAGTCAA CAGTC; CD44 Reverse GTTACACCCCAATCTTCATGT CCAC; Cortactin Forward AAAGCTTCAGCAGGCCAC; Cortactin Reverse TTTGGTCCTGTTTCAAGTTCC; 18S Forward CATTCGTATTGCGCCGCTA; 18S Reverse CGACGGTATCTGATCGTC. Reactions were performed using 1 ml of cDNA reverse transcribed from 10 mg total RNA, 0.4 mM of forward and reverse primers and 2 Â SYBR Green 1 master mix (Finnzymes, Oy, Espoo, Finland). Standard cycling procedures were employed with annealing temperatures of 511C used for the CD44 and 18S primers and 551C for the cortactin primer pair. Specific amplicon formation with each primer pair was confirmed by melt curve analysis. Gene expression was quantified relative to an 18S housekeeping gene. In some experiments cells were treated overnight before experimentation with the IkKinase-2 inhibitor, SC514 (20 mM; Calbiochem, UK), MEK1 inhibitor, U0126 (10 mM; Promega, WI), PI3K inhibitor, LY294002 (10 mM; Cell Signalling, MA), PKC inhibitor, bisindolemaleimide (10 nM; Calbiochem, UK) or the Src kinase inhibitor, PP2 (5 nM; Calbiochem, UK). The effects of the various inhibitors was compared against a vehicle control using the highest concentration of DMSO that cells were exposed to that is, 0.15%(v/v) DMSO.
Western blotting
Samples were collected as previously described (Draffin et al., 2004) and the final protein concentration in the supernatant determined using the BCA Protein Assay Reagent (Pierce, Rockford, IL). Samples (20 mg) were boiled for 5 min in an equal volume of reducing buffer (5 mM Tris/HCl pH 7.4, 4% (w/v) SDS, 20% (v/v) glycerol, 10% (v/v) mercaptoethanol, 0.2% (w/v) bromophenol blue), resolved on 12% polyacrylamide gels and electroblotted onto nitrocellulose membranes. Membranes were probed with a mouse anti-human CD44 monoclonal antibody (1:500 dilution, R&D Systems), a mouse anti-human Rel A antibody (1:500 dilution, Santa Cruz, Santa Cruz, CA), a mouse anti-cortactin (clone 4F11) monoclonal antibody (1 in 500 dilution, Upstate Biotechnology, NY) or a mouse anti-c-myc (9E10) monoclonal antibody (1 in 100 dilution, Santa Cruz), then treated with a sheep anti-mouse IgG/horseradish peroxidase conjugate (1:2000 dilution, Amersham) and immunoreactivity detected using chemiluminescence (Supersignal, Pierce). Equal loading of samples was confirmed by reprobing the membrane with a 1:2000 dilution of the b-tubulin antibody (Sigma).
Transfection of c-myc tagged murine cortactin into breast cancer cells Cells were transfected with 20 mg c-myc tagged murine cortactin using Genejuicet transfection reagent according to the manufacturer's instructions. Transfection efficiency was confirmed by immunoblotting with an anti-c-myc mAb and cortactin overexpression was confirmed by immunoblotting with an anti-cortactin mAb (Upstate Biotechnology).
RNAi-mediated depletion of cortactin, CD44 and p65 Rel A expression in cancer cells A specific cortactin siRNA oligonucleotide (5 0 -AAAGUG GAUAAGAGCGCCGUU-3 0 ) corresponding to the human EMS1/cortactin coding sequence and a scrambled oligonucleotide (5 0 -AAGCUGUAAGUGCAUAGGACC-3 0 ) were synthesized commercially (Qiagen, Chatsworth, CA). Cells were seeded and grown to 40% confluency, washed twice in sterile PBS, then incubated with a transfection cocktail comprising of OPTIMEM1, Oligofectamine (Invitrogen) and the siRNA or scrambled oligonucleotides at a final concentration of 50 nM for 4 h at 371C. Cells were replenished in 20% (v/v) FCS-enriched growth media overnight then subjected to a second transfection to ensure efficient suppression of cortactin expression. Transfected cells were incubated at 371C for 48 h before harvesting and experimentation. Depletion of cortactin expression in cells was confirmed by immunoblotting. Suppression of p65 Rel A-expression was performed as above using a commercially synthesized Rel A specific siRNA oligonucleotide (5 0 -GCCCUAUCCCUUUAC GUCA-3 0 ) and scrambled oligonucleotide (5 0 -AGUUCAAC GACCAGUAGUC-3 0 ) (Dharmacon, CO) at a final concentration of 200 nM. Suppression of CD44 using RNAi was performed as previously described (Draffin et al., 2004) .
NFkB luciferase reporter assay MCF7F-B5 cells (-tet) were transfected with 2 mg NFkB firefly reporter construct and 0.1 mg Renilla control reporter construct or with 2 mg pGL3-basic promoter-less luciferase construct and 0.1 mg Renilla (control for luminescence detection) using Genejuicet according to the manufacturer's instructions. Cells were incubated with the luciferase/Renilla constructs for 48 h before treatment with HA (100 mg/ml) over a 3-h period. Following HA treatment, 1 Â Passive Lysis Buffer (Promega, WI) was added to lyse the cells. Firefly and Renilla luciferase luminescence were measured over 15 s using the Dual-Luciferase Reporter Assay System (Promega, WI) according to the manufacturer's instructions. NFkB-driven luciferase was expressed as fold-change relative to pGL3 luciferase following normalization using the corresponding constitutive Renilla luciferase readings. Relative Luciferase Unit (RLU) fold-changes were calculated by comparison of NFkB-driven luciferase determined in the absence of HA stimulation and expressed as percentage control. In some experiments, cells were treated overnight with the IkKinase-2 inhibitor, SC514 (20 mM; Calbiochem) or the MEK1 inhibitor, U0126 (10 mM; Promega) before HA treatment for 2 h. The effects of the various inhibitors was compared against a vehicle control using the highest concentration of DMSO that cells were exposed to that is, 0.15%(v/v) DMSO.
Cell migration and invasion assays Invasion chambers were prepared by coating cell culture inserts (12 mm pore size, Costar) with 100 mg/cm 2 of Matrigelt alone or supplemented with HA at a final concentration of 100 mg/cm 2 in phenol red-free Dulbecco's modified Eagle's Medium (PRF-DMEM, Life Technologies). Assays were conducted as previously described using 5 Â 10 5 cells/well (Draffin et al., 2004) . In some experiments, invasive cells were alternatively stained with Hoechst reagent (H33258) for 30 min at room temperature, the membranes removed, mounted onto glass slides and individual cells counted under a fluorescence microscope (Leica DMLB).
Adhesion assays
Sub-confluent breast carcinoma cells were trypsinized, washed in adhesion media, (DMEM/0.1%BSA/20 mM Hepes, pH 7.4), resuspended at 1 Â 10 6 cells/ml in sterile complete buffer containing 10 mM Fura-4-AM acetoxymethyl ester and incubated for 1 h at 251C in the dark. Cells were pelleted, resuspended in serum-free media containing 1% (v/v) of probenicid (100 mM) for 30 min in the dark at 251C to permit de-esterification of the intracellular probe. Cells were resuspended at 3 Â 10 5 cells/ml in adhesion media and protected from light until experimentation. BMECs were seeded at a density of 1 Â 10 5 cells/ml in 96-well plates (for fluorescence work) and cultured to confluency. Before the assay, BMECs were washed twice with adhesion media. Labeled breast cancer cells were added (200 ml cell suspension per well) to confluent endothelial monolayers and incubated for the specified times at 251C. Non-adherent cells were removed using 2 Â 200 ml washes of adhesion media. Finally, plates were read in a fluorescent plate reader (Cytofluor 4000, Applied Biosystems, Warrington UK) at 371C using an excitation wavelength of 485 nm and an emission wavelength of 530 nm.
Statistical analysis of data
Differences between data points in functional assays (invasion and adhesion assays) were assessed for statistical significance using two-tailed Student's t-test comparisons (GraphPad Prism 4.0 software).
